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ABSTRACT 
Development of a highly refined human factor IX (hFIX) expression vector system is critical for establishing 
a durable hemophilia B gene therapy. Here we report construction of a series of retroviral vectors and iden-
tification of an optimal basic structure and components for expressing hFIX in skeletal muscle cells. These 
vectors, which are derived from Moloney murine leukemia virus ( M o M L V ) with its enhancer sequence in the 
3' long terminal repeat (LTR) deleted, contained internal hFIX expression units inserted in forward config-
uration without or with a viral vector intron sequence (pdL or pdLIn vector frame, respectively) or in in-
verted configuration without a viral vector intron sequence (pdLi frame). Internal expression units contained 
a hFIX c D N A or hFIX minigene (hlXml or hIXm2) derived from the hFIX c D N A by insertion of a short-
ened first intron sequence of the hFIX gene. Regardless of the promoter and vector frame used, both hlXml 
and h I X m 2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX 
transcriptional control units of these vectors were composed of various promoters linked with or without the 
muscle creatine kinase enhancer (Me) sequence. Promoters tested included those of a-actin (aA775), /3-actin 
(/SA280), cytochrome oxidase (CO1250 and CO650), myogenin (Mgl031 and Mg353), and Rous sarcoma virus 
(RSV). /SA200, which was derived from /3A280 by eliminating potential polyadenylation sites, was also tested. 
As extensively examined with the myogenin promoter, presence of one or multiple copies of M e in the vec-
tors elevated the expression activity in myotubes by 4.5- to 19-fold over those without M e , but not signifi-
cantly in myoblasts. Similar enhancements in expression activity with M e were also observed with other pro-
moters, except those of R S V and C O . The latter two showed only modest enhancements in the presence of 
M e . As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters 
with four copies of M e in the three different vector frames was /3A280 = ^A200 > Mg353 > Mgl031 = R S V « 
C O 6 5 0 ~ aA175 > CO1250. One exception was that CO650 showed significantly less activity in pdLi-type 
vectors than in the pdLIn vectors. Based on the systematic analyses of various structural components, a group 
of pdLi vectors consisting of i8A200, two to four copies of M e , and hIXm2 was identified to have the optimal 
basic vector structure to be used in retrovirus for hFIX expression in differentiated skeletal muscle cells. The 
present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based 
on skeletal muscle-targeted hFIX gene transfer. 
O V E R V I E W S U M M A R Y ™3n factor IX minigenes, various muscle-specific or non-
specific promoters, and muscle creatine kinase enhancer. 
Skeletal muscle cells may serve as an efflcient medium for These vectors were tested systematically to determine an op-
systemic production of transgene products in a gene ther- timal basic structure for producing factor IX in mouse 
apy Retroviral vector constructs were prepared using hu- skeletal muscle cells. The basic retroviral vector structure 
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for an optimal expression of factor IX in skeletal muscle 
cells m a y contain an internal factor IX expression cassette 
composed of a /3-actin promoter, muscle creatine kinase en-
hancer, and human factor IX minigene in a reverse orien-
tation relative to the 5' long terminal repeat. 
INTRODUCTION 
SKELETAL Muso-Es comprisc a large portion of human and 
animal bodies, and are easdy accessible for various manip-
ulations. Skeletal myoblasts can be prepared from muscle tis-
sue biopsy samples and expanded in culture to large numbers 
(Webster et al, 1988; Rando and Blau, 1994). Inttamuscularly 
implanted myoblasts genetically modified in culture not otdy 
fuse with the existing host myofiber cells or among themselves, 
generating new muscle cells, but also survive as muscle pre-
cursor cells (satellite cells) (Yao and Kurachi, 1993). Skeletal 
muscle has also been shown to have high systemic delivery ef-
ficiency of various ttansgene products (Yao and Kiu-achi, 1992). 
Accordingly, muscle-targeted gene ttansfer has been intensively 
smdied for its potential application for estabhshing gene ther-
apies for various disorders (Barr and Leiden, 1991; Yao and 
Kurachi, 1992; Bansal et al, 1994; Baque et al, 1994; 
Hamamori et al, 1995). The potential of myoblast-mediated 
gene ttansfer to be developed mto a durable gene delivery 
method has been extensively tested for various genes such as 
factor rx (Dai et al, 1992; Yao and Kurachi, 1992; Yao et al, 
1994), growth hormone (Dhawan et al, 1991; Dahler et al, 
1994), erythropoietin (Hamamori et al, 1995), glucocerebrosi-
dase (Bansal et al, 1994), and otiier protems (Jiao et al, 1993). 
Muscle-targeted gene ttansfer may be achieved by various 
methods, such as in vivo direct gene ttansfer usmg vkal vec-
tors (Ragot et al, 1993; Vmcent et al, 1993; Acsadi et al, 
1995; Dai et al, 1995) and naked vector D N A s (Davis et al, 
1993a,b; Manthorpe et al, 1993) or ex vivo gene ttansfer (my-
oblast-mediated gene ttansfer) (Barr and Leiden, 1991; Dhawan 
et al, 1991; Yao and Kurachi, 1992, 1994; Salvatori et al, 
1993; VitadeUo et al, 1994; Hamamori et al, 1995; Trivedi 
and Dickson, 1995). 
For estabhshment of a diuable gene therapy mediod, devel-
opment of a highly refined gene delivery system has become a 
cmcial issue (Mdler, 1992a,b). Rettovkal vector systems have 
been extensively used to mttoduce foreign genes into various 
target cells mcludmg skeletal muscle cells (Dhawan etal, 1991; 
Yao and Kurachi, 1992; Yao etal, 1991, 1994; Mdler, 1992b)! 
Most rettovkal vectors used to date are derivatives of Moloney 
muihie leukemia vkus ( M o M L V ) (Mdler, 1992a,b). Aldiough 
its long termmal repeat (LTR) promoter is generally sttong m 
various cell types and also can dkect stable ttansgene expres-
sion hi skeletal muscle cells (Yao et al, 1994), die L T R pro-
moter is not differentiated muscle cell specific. Expression of 
foreign genes under its conttol is not elevated much upon my-
oblast differentiation. Transcriptional conttol units with various 
cell type-specific promoters and enhancers m rettovkal vectors 
can confer cell-specific and persistent expression of die ttans-
genes (Pettopoulos et al, 1992; Anson and Occhiodoro 1994-
Dahler et al, 1994). 
Recently, we reported that primary mouse skeletal myoblasts 
ttansduced with recombuiant rettovual vectors containuig a hu-
man factor IX (hFIX) c D N A under conttol of die L T R or 
chicken )3-acthi promoter (/3A) widi murine muscle creatme ki-
nase ( M C K ) enhancer (Me) can express hFIX at a high level, 
equivalent to tiiat observed for C2C12 cells (estabUshed murine 
myoblast line) (Yao and Kurachi, 1992; Yao et al, 1994). The 
in vivo hFIX expression levels of the primary myoblasts were, 
however, significantly lower than those observed with C2C12 
cells hi a sunilar experunent (Yao et al, 1994). It was con-
cluded that the observed difference between the primary my-
oblasts and C2C12 cells is likely due to diek cellular proper-
ties, such as fusion efficiency and in vivo stabUity, rather than 
due to a possible promoter inactivation as reported by others 
(Palmer er a/., 1991; Scharfmann etal, 1991; Dai etal, 1992). 
These observations sttongly suggested die necessity for exten-
sive refinement of two aspects of the muscle-targeted gene de-
livery system, die hFIX expression vector stmcture and the cel-
lular procedures involved. 
The present paper deals with the fkst phase of our intensive 
smdies on the hFIX expression vector, defining its stmctural 
components and organization requked for an optimal produc-
tion of hFIX in differentiated muscle cells (myombes). W e have 
constmcted a series of hFIX expression vectors in three differ-
ent vector frames derived from M o M L V , with a battery of dif-
ferent muscle-specific and nonspecific promoters combined 
with M e and hFIX minigenes. They were constructed so that 
the hFIX expression cassette can be easUy ttansferred into var-
ious other viral and nonvkal vector systems for further testing. 
These vectors were subjected to systematic expression analy-
ses with primary mouse skeletal myoblasts and myombes, thus 
establishing the basic stracture in rettovkal vector frame for the 
optimal hFIX expression in muscle ceUs. 
MATERIALS AND METHODS 
Construction of hFDC expression vectors 
Promoter Sequences: Muscle-specific and nonspecific pro-
moters were prepared by excismg from die previously prepared 
vectors, or by polymerase cham reactions (PCR) usmg 5' and 3' 
primers widi Xho I and B a m HI Ihiker sequences, respectively, 
and genomic D N A or cloned D N A fragments as die template^ 
(Table 1). P C R was carried out as previously described (Yao et 
al, 1994), and resulting D N A fragments contauung various pro-
moter sequences were digested widi Xho I and B a m HI, purified 
by agarose gel electtophoresis, and mserted mto various expres-
sion vectors at thek Xho VBam HI sites. Specific piwedures for 
preparation of each promoter sequence are described below. 
A long myogenm promoter, Mgl031, which contams die se-
quence-spannmg nucleotide -1,013 to -H8 of die myogenm 
gene, was derived by P C R widi a pak of primers and 
pMyol565CAT as die template (Edmondson et al, 1992) 
(Table 1). The P C R product was digested widi Xho I aiid B a m 
m , generating Mgl031 widi Xho I and B a m HI sites at its 5' 
and 3 ends, respectively. A short myogenm promoter sequence 
tra^ent, Mg353, containmg tiie region spamimg nucleotides 
335 to -M8 of die myogenin gene, was prepared by remov-
ing the 5 halfof MgI031 (nucleotides -1,031 dirough -334) 
by cleaving widi Sma I at nucleotide -334. A Xho I Ihdcer was 
then hgated at die Sma I site foUowed by Xho I digestion 
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5' forward: 5'-CAT C T C G A G T A C 
AGG GGA ACG CCA GGG C-3' 
3' reverse: 5'-TAT GGA TCC CCC 
AAG CTC CCG CAG CCC C-3' 
5' forward: 5'-CCG CTC GAP GTC 
CCT AGA CTG AGG CAC-3' 
5' forward: 5'-CCG CTC GAG CGA 
CCT CCC GGG GCC AGC-3' 
3' reverse: 5'-CGC GGA TCC AGT 
TGT AGG GCT GAG CTC CT-3' 
5' forward: 5'-ACT GCT CGA GGT 
GGC CCT CTG TGC GGT GG-3' 
3' reverse: 5'-CAC TGG ATC CGG 
GTA GCT ACA ACT GCT ACT-3' 
5' forward: 5'-CCT CCT CGA GGG 
CCC TTr TTT TTT TTG TGC 
AGC GAT GGG GG-3' 
3' reverse: 5'-CAC GGA TCC TAG 







nt-588 to -569 
nt -1-62 to -1-43 
nt -689 to -672 
nt +86 to -1-66 
nt-1199 to-1174 
nt-1000 to-1018 











Lomax et al., 
1995 
Taylor et al.. 
1988 
Kost et al., 
1983; 
Yao et al., 
1994 
*The underlined sequences indicate restriction sites buUt into the P C R primers. The italic Ts 
in /3A200 5' primer sequence indicate they are different from the original gene sequence with ade-
nine residues. 
Bovine cjrtochrome oxidase ( C O S H ) promoter sequences were 
prepared by P C R usmg p C O X 8 H C A T contauung bovme C 0 8 H 
5'-flanking sequence as the template (Table 1) (Lomax et al, 
1995). Long (1,251 bp) and short (650 bp) forms of die C O pro-
moter, C O 1251 and CO650, were prepared by using either one 
of the two 5' forward primers (corresponding at nucleotides 
-1,189 to -1,170 and nucleotides -588 to -569) and a com-
mon 3' primer (nucleotides -1-62 to -1-43) (Table 1). 
Human a-acthi promoter (qA775) was prepared by P C R us-
ing human genomic D N A as the template (Taylor et al, 1988) 
(Table 1). Because of the presence of an Xho I site at nucleotide 
-86 within die a A promoter sequence, the P C R product was 
fkst digested with B a m HI and then subjected to partial diges-
tion with Xho I, thus obtaming a All 5. 
A Rous sarcoma vkus (RSV) promoter firagment was obtamed 
ftom pERT9 (Invittogen) as follows. A unique Xho I site present 
m the R S V promoter sequence contamed m pERT9 was elimi-
nated by Xho I digestion foUowed by blunt-endmg and religa-
tion. A Sal l-Bam HI fiagment (-600 bp) contakimg die R S V 
promoter sequence was isolated from die resulting vector and m-
serted mto pBluescript vector (Stiatagene) at Sal VBam HI sites, 
generatmg pBluescriptRSV. The Xho VBam HI fragment con-
tauung R S V promoter sequence was dien generated by digestion 
of pBluescriptRSV widi Xho I and B a m HI. 
Chicken /3-actin promoter (/3A280, contauung a region span-
mng nucleotides -1,279 tfuough -1,000) (Kost et al, 192,3) was 
derived ftom a hFEX expression vector, pdLMe2/8A280hIX (pre-
viously named p d L M M B A K ) , constracted in our previous study 
(Yao et al, 1994). A short form of the ;3A promoter sequence 
(j3A200) contaming the region nucleotides —1,199 through 
— 1,000 was prepared by PCR usmg this vector as the template 
and primers listed in Table 1. The 5' primer contained thymine 
residues replacing the adenine residues present in die original 
gene sequence at nucleotides —1,197, —1,196, and —1,193 (ital-
ics in Table 1) to disrapt potential polyadenylation site sequences. 
The 5' forward primer contained Xho I and Apa I linker sequences 
in its 5' end region, whUe the 3' reverse primer contamed Avr II 
and Bam HI sequences. These sites were included to make the 
fragment versatile m transferring mto other vectors. 
M C K Enhancer (Me): The region (hereafter referred to as 
Me) spaiming nucleotides -1,351 to -1,050 ofthe 5'-flank-
ing sequence of mouse M C K gene contains a sttong muscle-
specific enhancer activity (Stemberg et al, 1988). A fragment 
containmg two M e copies (Me2) was constracted by inserting 
two 301-bp Xho I fragments (a smgle copy of Me), previously 
prepared (Yao et al, 1994), into pBluescript vector at Xho I 
site hi a tandem orientation. The Xho I site in between the two 
M e sequences was eliminated by blunt-ending. Fragments con-
taining four copies of M e (Me4) in a tandem orientation was 
constracted in a simUar manner by using M e 2 as the starting 
fragment. 
Vector Frames: Three different vector frames, pdL, pdLIn, 
and pdLi, were used in constracting the hFIX expression vec-
tors (Fig. IA). 
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FIG. 1. A. Three basic rettovkal vector frames used to construct new hFIX expression vectors. All vectors are derivatives of 
M o M L V . pdL indicates a vector frame with the 3' L T R with its enhancer region deleted. pdLIn has the same stracture as pdL, 
except that h is inserted witii the MFG-derived vector intton sequence. pdLi has the same vector frame as pdL, except that the 
mternal FIX expression umt is inserted in an inverted orientation with regard to the 5' LTR. B. Intermediate constracts used for 
preparing pdLIn- and pdLi-type vectors. The unique Bam HI site in p M F G was converted to Xho I, and a Hind Ul-Xho I frag-
ment derived from p M F G was inserted into the Hind lll-Xho I sites of pdLMgl031, replacuig the original Hind lU-Xho I por-
tion, generating pdLInMgl031. pdL(XX) and pdL(BB) were derived from pdLMgl031 by converting its B a m HI site to Xho I 
and the Xho I site to Bam HI. They were used to generate pdLiMgl031 (see text). LTR, Long termmal repeat; SD, splicmg donor 
site; SA, splicing acceptor site; i//, viral packaging signal; Me, M C K enhancer; intton, shortened fkst intton of hFDC gene in its 
namral position; I-Vm, exons of the FIX gene. Arrows show die sites and the dkection of ttanscription. The X in the 3' L T R 
indicates the deleted enhancer region. Relevant resttiction sites are shown with short vertical bars. The constiucts shown are in-
serted in the pBR322 vector at the Hind III and Eco RI sites. 
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pdL vector frame was derived from pdLMe2j8A280hIX (Yao 
et al, 1994) by deleting its Me2)3A280hEX portion with Xho 
VBam HI digestion. This vector has its U3 enhancer region (178 
bp) in die 3' LTR deleted (WUson et al, 1988). pdLMe2-
/3A280hIXml was constmcted by replacing the hFIX cDNA in 
pdLMe2j8A280hIX with a hFIX minigene, hlXml, which con-
tains die first intton sequence of the hFIX gene with its middle 
4.8-kb sequence ttuncated out of die original 6.2 kb (Kurachi 
et al, 1995). The Mgl031 fragment prepared as described 
above was inserted into the pdL vector frame, thus generating 
pdLMgI031 (Fig. IB). hDCml was then inserted into diis in-
termediate vector at the unique Bam HI site, generatmg 
pdLMgl031hIXml. Four copies of M e (Me4) were then in-
serted into this vector at the Xho I site, producing 
pdLMe4MgI031hEXml. The Mgl031 promoter sequence in 
these vectors was then replaced by various other promoter se-
quences (Mg353, /3A280), thus generatmg a series of pdL-type 
vectors. 
pdLIn vector frame was derived from plasmid pdLMgl031 
and p M F G (Dranoff et al, 1993) (Fig. IB). p M F G contained 
an intton sequence (In) in the rettovkal vector frame that was 
derived from the splicing donor sequence (SD) located 5' to the 
packaging sequence region (ip), and a splicing acceptor se-
quence (SA) derived from the envelope gene sequence. A 
tmique Bam HI site located downstteam of the vkal intton se-
quence of p M F G was converted to an Xho I site by ligating an 
Xho I linker. The plasmid D N A was then cleaved with Xho I 
and Hind m (Fig. IB), generating a 2.2-kb Hind lll-Xho I frag-
ment containing the 5' LTR, packaging signal sequence, and 
complete splicing sequence. This fragment was then inserted 
into pdLMgl031 at Hind Ul/Xho I sites, replacmg the corre-
sponding Hind Ul-Xho I fragment (2.4 kb), thus generating 
pdLInMgl031. hlXml and M e (I, 2, and 4 copies) were then 
inserted into these vectors at the unique Bam HI and Xho I sites 
in a simUar maimer as described for pdL vectors, generating 
the pdLIn vectors witb Mgl031 and hlXml. The Mgl031 pro-
moter sequence was then replaced with various other promoter 
sequences (Mg353, /3A280, CO1250, CO650, and RSV), thus 
resulting in a series of pdLIn-type vectors. 
The pdLi vector frame, which contains an intemal hFIX ex-
pression unh in an inverted orientation relative to the 5' LTR, 
was derived from the pdL vector frame. The unique Xho I and 
Bam HI sites in the pdL vector frame were converted to Bam 
HI and Xho I, respectively. The resulting two intermediate con-
stiucts, pdL(BB) and pdL(XX), which have a unique Bam HI 
or Xho I site, respectively (Fig. IB), were then digested with a 
combination of Hind HI and Bam HI or Hind HI and Xho I, 
generating a 2.4-kb Hind UI-Bam HI fragment containmg 5' 
LTR, SD, and if/ signal of pdL, or 5.6-kb Xho l-Hind HI frag-
ment contaming 3' LTR and pBR322 backbone sequence. 
These two fragments and Mgl031 fragment widi Xho VBam HI 
ends were ligated, thus producing pdLiMgl031 with ks 
Mgl031 sequence in an inverted orientation relative to die 5' 
LTR. A Bam Hl-Bgl H fragment (0.38 kb) contaming the 3' 
unttanslated region of the hFIX gene with ks poly(A) signal 
sequence was prepared from a hFIX expression vector, 
p-416hIXml (Kurachi etal, 1995). This fragment was inserted 
into pdLiMgI031 at the Bam HI site in the same dkection as 
the Mgl031 promoter, generating pdLi(pA)Mgl031. hlXml 
and Me2 or Me4 were then inserted into the vectors at Bam HI 
and Xho I sites, respectively, generating pdLihEXmlMg-
1031, pdLihIXmlMgl031Me2, and pdLihIXmIMgl031Me4. 
Mgl031 in these vectors was then replaced by various other 
promoters (Mg353, /3A280, ̂ A200, aA775, and CO650), and 
hlXml in some constracts was replaced with liIXm2, another 
hFIX minigene, thus generating a series of pdLi-type vectors 
(Table 2). hIXm2 was derived from hlXml by further shorten-
ing the intton sequence by 1.1 kb leaving only a 0.3 kb mtton 
sequence of the hFIX gene (Kurachi et al, 1995). 
All PCR-derived D N A fragments and ligation sites of the es-
sential components in the newly constracted vectors were se-
quenced to confirm their correct stractures. The vector plasmid 
DNAs used for ttansfection experiments were purified using a 
Qiagen plasmid kit or two cycles of ulttacentrifugation band-
ing through CsCl gradient. 
Cells and culture conditions 
Primary skeletal myoblasts were isolated from SCID mouse 
hind leg muscles as previously described (Yao and Kurachi, 
1993) and used in the present expression assays. Cells were 
grown in Dulbecco's modified essential medium (DMEM) 
(GIBCO/BRL) supplemented with 2 0 % fetal calf seram (FCS), 
0.5% chicken embryo exttact (CEE) (GIBCO/BRL), and sttep-
tomycin and peniciUin. All cell cultare dishes were kept at 37°C 
in humidified incubators with 5% CO2. 
Enzyme-linked immunosorbent assay of HFIX 
hFIX produced was quantified by hFIX-specific enzyme-
lmked immunosorbent assay (ELISA) using a murine anti-hFIX 
monoclonal antibody (AHIX-5041, Haematologic Tech-
nologies Inc.) as the catching antibody and rabbk polyclonal 
anti-hFIX as the detecting antibody (Yao et al, 1991; Kurachi 
et al, 1995). A microtiter plate reader (Bio-Tek model EL312e) 
was used for quantitation. This ELISA detected neither bovine 
nor murine factor DC at any significant level, permittmg a pre-
cise determination of hFIX produced at sub-nanogram levels in 
the culture medium. 
Transient expression of hFIX in culture 
For assaying the ttansient expression activities of the vec-
tors, LIPOFECTAMINE-mediated ceU ttansfection was used 
accordmg to the manufacturer's instiuction (GIBCO/BRL). 
Twenty-four hours prior to ttansfection, primary myoblasts 
were plated at a density of 2 X lO'/well m six-weU ceU cultare 
plates (Coming). Expression vector D N A (2 pg) and pCHllO 
D N A (;8-Gal expression vector, 0.2 pg) (Herbomel et al, 1984) 
were mixed widi LIPOFECTAMINE (30 pg) hi Opti-MEM 
(GIBCO/BRL; total volume 100 pl) and incubated at room tem-
perature for 15 mm. Aliquots of Opti-MEM (900 pl) were dien 
added and the DNA-LIPOFECTAMDflE complexes formed 
were added to each weU with ceUs, which were in advance 
rinsed once with Opti-MEM. CeUs were then incubated at 37°C 
under 5 % CO2 for 6 hr, followed by addition of 1-ml aliquots 
of die myoblast cultare medium. Twenty hours later, the 
DNA-LIPOFECTAMINE ttansfection medium was removed, 
and the cells were washed twice witii phosphate-buffered saline. 
Two miUUiters of hFDC assay medium (DMEM, 2 0 % BaS04-
tteated FCS, 10 /ig/ml Vitamm Kl, and 0.5% CEE) were then 
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Table 2. Human Factor DC Expression Vectors 
Vector 
Type* 
Vector Name Promoter 
(Size in bp) 
M e hFIX hFIX 
(Copy No.) Gene (ng/ml)* 







pdLIn 8 pdLInMgl031hIX 
9 pdLInMgl031hIXml 
10 pdLInMeiMgl031hIXml 























LIXSN 34 LIXSN 
Murme Myogenin (1031) 
Murine Myogenin (1031) 
Murine Myogenin (353) 
Murine Myogenin (353) 
Chicken P-Actin (280) 
Chicken p-Actin (280) 
Chicken p-Actin (280) 
Murine Myogenin (1031) 
Murine Myogenin (1031) 
Murine Myogenin (1031) 
Murine Myogenm (1031) 
Murine Myogenin (1031) 
Murme Myogenin (353) 
Murine Myogenin (353) 
Chicken P-Actin (280) 
Chicken P-Actin (280) 
CalfCyto Oxidase (650) 
Calf Cyto Oxidase (650) 
CalfCyto Oxidase (1250) 
Rous Sarcoma Viras 
Rous Sarcoma Viras 
Murme Myogenin (1031) 
Murine Myogenin (1031) 
Murine Myogenin (1031) 
Murine Myogenin (353) 
Murine Myogenin (353) 
Chicken P-Actin (280) 
Chicken P-Actin (280) 
Chicken p-Actin (200) 
Chicken P-Actin (200) 
Chicken p-Actin (200) 
Calf Cyto Oxidase (650) 
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c D N A 10.2±0.7 
*pdL, Rettovkal vector frame with its 3' LTR enhancer region (178 bp) deleted; pdLhi, vector frame widi a splicmg unit de-
rived from the M F G vector and die 3' LTR enhancer region deleted as in pdL; pdLi, vector frame widi die same vector backbone 
as pdL, except the inverted orientation of the intemal hFIX expression unit in relation to 5' LTR. 
**hFIX produced mto die cultare medium of myombes on day 7 shown in ng/ml, which is equivalent to diose m ng/lO^ cells/24 
hr. Average hFDC production levels with SD (n = 4-6 from two to four independent experiments) are shown The expression lev 
els of different vectors were normalized to the level of one to two vectors commonly tested in different sets of experiments 
added. The medium was collected every 24 hr and the same 
volume of fresh medium was added. After 48 hr, myoblast dif-
ferentiation medium containing 2 % BaS04-tteated horse seram 
(HS) was added to two out of four wells for each constract. 
This was replaced with fresh medium every 24 hr up to day 6 
to induce myoblast differentiation into myotabes. Cell numbers 
at the tune of switching to the differentiation medium was about 
2 X lO^weU at 80-90% confluency. Under these conditions, 
differentiation was completed in 2.5-3 days. At the end of day 
6, die medium was replaced widi die hFDC assay medium and 
incubated for additional 24 hr. Amounts of hFDC protem pro-
duced into the medium were quantified by ELISA and nor-
malized to die ̂ -Gal activity (mternal conttol for ttansfection 
efficiency). Myoblast cell numbers, ;8-Gal activities, and total 
cellular protem amounts were determmed using die remammg 
two wells at the end of day 2. ̂ -Gal activity was detennmed 
according to Eustice et al (1991) widi mmor modifications. 
Ihe total protein concenttation of ceU exttacts was measured 
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by die Bio-Rad protein assay kit (Bio-Rad Laboratories) ac-
cording to die manufacturer's instiiiction. 
pLDCSN and pdLMe2/3AhDC, which we previously reported 
(Yao etal, 1991,1994), were used as reference expression vec-
tors in assaying die newly constiucted vectors for thek ttan-
sient expression activities. 
Northem blot analysis of muscle cells transfected with 
hFIX expression vectors 
Polyadenylated RNAs were prepared using the QuickPrep 
Micro m R N A purification kit (Pharmacia Biotech) from cells 
on day 2 (myoblasts) and day 5 (myotabes) after ttansfection, 
and subjected to Nortiiem blot analysis as previously described 
(Kurachi et al, 1995). hFDC c D N A labeled witii 32p to a spe-
cific activity of ~ 1 X 109 cpmlpg was used as die hybridiza-
tion probe for blotted filter membranes. After sttipping off die 
hFDC probe, die membrane was rehybridized with the ̂ ^p.ig. 
beled human 18S ribosome R N A c D N A (American Type 
CulUue Collection) as conttols for equal loading of m R N A sam-
ples. R N A levels were quantified by a Phosphorlmager 
(Molecular Dynamics) and hFDC m R N A levels were normal-
ized to those observed for 18S ribosome R N A . 
RESULTS 
Construction of hFIX expression vectors arui their 
expression activities 
hFIX expression vectors and ttansient expression activities 
assayed with myotabes are summarized in Table 2. All the vec-
tors contained an intemal hFIX expression cassette inserted in 
one of the three MoMLV-derived vector frames (Fig. IA). 
Intemal hFIX expression cassettes consisted of various combi-
nations of a promoter (either muscle-specific, vkal, or house-
keeping gene promoters), muscle creatine kinase enhancer (Me) 
in different copy numbers, and a hFIX minigene in two differ-
ent forms. Promoters tested included those of /3A in two lengths 
(i8A280 and j8A200, the latter with all potential polyadenyla-
tion sites in the complementary sttand eUminated), M g with two 
different lengths (Mgl031 and Mg353), muscle-specific C O 
witil two different lengdis (CO 1250 and CO650), RSV, and a A 
(aA775). hFDC sequences used were c D N A (1.4 kb) and two 
minigenes, hDCml (2.9 kg in length) and hIXm2 (1.7 kb), con-
taining trancated fkst-intton sequences. These vectors were sys-
tematically tested in a ttansient expression assay system with 
skeletal myoblasts and thereof derived myotabes to determine 
the relationship between various stractural components and 
hFIX expression activity. Efficiency of myoblast ttansfection 
with L I P O F E C T A M I N E in the present stady was approxi-
mately 20%. 
Effects of minigenes 
As shown in Fig. 2, pdLInMg 1031 hDCml showed 10- to 14-
fold higher expression level in myotabes over that of 
pdLInMgl03IhIX, indicating gross elevations in hFDC expres-
sion in die presence of hlXml over diat widi hFDC cDNA. 
Similar elevation due to the use of hlXml was also observed 
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FIG. 2. Transient expression of hFIX by pdLInMg-
lOSlhDCml (•) and pdLInMgl031hIX (O) from skeletal mus-
cle ceUs. Details of experimental conditions are described in 
Materials and Mediods. Murine myoblasts (2 X lO'/weU) were 
plated in a six-well plate 1 day prior to ttansfection. Cells were 
ttansfected with hFIX expression vector D N A s and p C H U O 
plasmid D N A (intemal ttansfection efficiency conttol) using 
lipofectamine-mediated ttansfection. Twenty hours later, the 
ttansfection medium was replaced with 2 ml of fresh complete 
growth medium (day 1). The medium was collected for ELISA 
every 24 hr and was replaced with the fresh medium. 
Differentiation medium with 2 % horse seram was added to cells 
beginning on day 3 tiu-ough day 6. Then die fresh growdi 
medium was added to the cells for an additional 24 hr. CeU 
number at the beginning of differentiation was about 2 X 
10^/weU. Expression levels shown in ng/ml are equivalent to 
those in ng/1 X 10* ceUs per 24 hr. Vertical bars indicate stan-
dard deviations (n = 4). Arrow indicates the time point of 
switching to the differentiation medium. 
hIXm2 was only shghtiy lower than that of hlXml, as shown 
by comparison between pdLihIXmlMg353Me4 and pdLihl-
Xm2Mg353Me4, pdLihIXml)3A280Me4 and pdLihIXm2-
j3A280Me4, or pdLihIXmI/3A200 and pdLihIXm2/3A200 
(Table 2). These results were in accord with our previous ob-
servations with the hFDC promoter (Kurachi et al, 1995). 
Therefore, hFDC minigenes were included in the newly con-
stracted hFIX expression vectors in this stady. 
Effects of different vector frames 
Three different rettovkal vector frames, pdL, pdLIn, and pdLi, 
designed in the present stady, permitted us to test several criti-
cal aspects of the basic stmctures of FIX expression vectors. 
pdLIn vectors without M e (pdLInMg353hIXml and 
pdLLiMgl031hIXml) showed only marginally (20-30%, p = 
0.052) higher expression activities than pdL vectors (pdLMg-
353hIXml and pdLMgl031hIXml) (Table 2), suggesting only 
a minor contribution, if any, of the M F G vector intton sequence 
with the 5' L T R promoter to the overaU expression levels. As 
shown for pdLMe4Mg353hIXml and pdLInMe4Mg353-
hDCml, as well as for pdLMe4Mgl031hIXml and pdLInMe4-
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FIG. 3. Comparison of ttansient expression activities among 
the representative pdLIn and pdLi vectors with the Mgl031 pro-
moter in the absence and presence of Me4. Experimental con-
ditions are simUar as described in Fig. 2. Transient expression 
activities of the vectors from myotubes were analyzed on day 
7. Thin lines with vertical bars indicate standard deviations of 
three independent experiments. 
and botb pdL- and pdLIn-type vectors expressed hFIX equally 
weU. SimUarly, in die presence of Me, /3A280 could drive hFIX 
expression equally well for both pdL and pdLIn-type vectors. 
pdLi vectors were designed to test the hFIX expression unit 
in the inverted orientation. Such vector stracture was consid-
ered to be important in avoiding splicing of the intton sequence 
contained in the hFIX minigenes during rettovkal R N A genome 
production in the packaging cells (Cone et al, 1987; Miller et 
al, 1988). pdLihIXmlMgl031, which contamed no Me, 
showed only 2 7 % and 2 1 % expression levels of those of 
pdLMgl031hDCml and pdLInMg 1031 hDCml, respectively. In 
the presence of Me, however, pdLihIXmlMgl031Me4 ex-
pressed hFIX at the levels equivalent to the counterpart con-
stracts of pdL and pdLIn-type vectors, pdLMe4Mgl031hIXml 
and pdLhiMe4Mg 1031 hDCml (Fig. 3, Table 2). 
Effects of MCK enhancers 
As typically shown for a series of pdLInMg 1031 hlXml vec-
tors witb one, two, and four copies of M e (vectors 10-13 in 
Table 2), the overall hFIX expression level was elevated 2.0-, 
3.7-, and 4.5-fold over that with no M e (pdLInMg 103 IhlXml) 
(Fig. 4). The first one and two copies of M e gave the most dras-
tic increases in expression, while the additional two copies pres-
ent in M e 4 gave less enhancing effects per M e copy. 
pdLInMg353hIXml series vectors, which contained the short 
M g promoter also showed sknilar enhancements with increas-
ing number of M e copy (Table 2). Similar general effects of 
M e were also observed with both pdL- and pdLi-type vectors. 
Among the three types of vectors, however, enhancing effects 
of M e were most dramatic with pdLi-type vectors as typically 
shown for pdLihDCmlMglOSl series of vectors (Table 2, Fig. 
5). In comparison to pdLihDCmlMgl031, which expressed 4.4 
ng/ml of hFIX on day 7, vectors with two and four M e copies 
(pdLihIXmlMgl031Me2 and pdLihDCmlMgl031Me4, re-
spectively) expressed 46.4 and 85.9 ng/ml (10- and 19.5-fold 
enhancements), respectively (Fig. 5). The substantial differ-
ences in the enhancement rate between pdLi and the other two 
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vector types (pdL and pdLhi) are due to die lower basal activ-
ity of pdLi vectors in die absence of M e than diose of pdL and 
pdLhi vectors (Table 2). As mentioned above, the hFDC ex-
pression levels of pdLi, pdL, and pdLhi vectors widi four M e 
copies (Me4) are not significantiy different. 
Effects of different promoters 
Different promoters tested in the hFIX expression vectors 
showed substantially varied hFIX expression activities and 
muscle cell specificity. Vectors with Mgl031 promoter showed 
marked preference for myotubes, as expected, from the previ-
ous report (Edmondson et al, 1992) (Figs. 2 and 6). W h e n the 
culture medium was switched to the differentiation medium on 
day 2 (end of 48 hr after ttansfection), hFDC expression of 
pdLInMg 1031 hDCml rose from 1.6 ng/ml medium with my-
oblasts to 21.0 ng/ml on day 7 with myotubes, a 13.1-fold hi-
crease (Fig. 6). This large hicrease was not due to a modest hi-
crease in myoblast cell number ( < 2 0 % at most) observed after 
switchmg die medium to a differentiation medium. Tbe ob-
served myotabe-specific increase in expression was also ob-
served with die short form of myogenin promoter (Mg353). 
pdLhiMg353hDCml expressed 33.1 ng/ml on day 7, a 13.2-fold 
increase over that on day 2 (2.5 ng/ml medium). Vectors with 
Mg353 showed about 20-60% higher expression levels than 
with Mgl031 (p = O.OIO) (Figs. 6 and 7). O n day 7, 
pdLInMg 103 IhlXml expressed 21.0 ng/ml medium of hFDC 
(average of four independent experiments), whereas the 
pdLInMg353hIXml expressed 33.1 ng/ml medium (Table 2). 
Higher expression levels were also observed for Mg353 over 
Mgl031 in the presence of Me, regardless of different vector 
frames (pdL or pdLi). 
CO650 and C O 1250 showed similar differentiated muscle 
cell-specific expression (data not shown). CO650 also had a 
significandy higher basal activity than C O 1250. pdLInCO650-
hDCml expressed 53.9 ng/ml medium of hFIX (average of three 
independent assays), whereas pdLInCO1250hIXml gave only 
8.8 ng/ml (Table 2). 
CO650, RSV, and i3A280 promoters had simUar basal pro-
moter activities, which were substantially higher dian those of 
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FIG 4. Effects of increasing copy numbers of MCK enhancer 
(Me) on ttansient expression of hFDC by pdLhiMgl031DCml 
Averages of hFDC amounts produced from myotub'e (d ^vTin 
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FIG. 5. Expression of hFDC in myoblasts and myotubes by 
pdLi vectors witii Mgl031 promoter and M C K enhancer (none, 
two, and four). Expression conditions were simUar to diose de-
scribed hi Fig. 2. (O) pdLihDCmlMgl031; (•) pdLhlXml-
Mgl031Me2; (D) pdLihDCmlMgl031Me4. Arrow indicates 
die medium switch for cell differentiation. Vertical bars are 
standard deviations of tripUcated assays. 
Mgl031 and Mg353 (Table 2, Fig. 7a). In the presence of Me4, 
however, Mg353 gave a 3 0 % and 2 3 % higher activities than 
tiiose of CO650 and RSV, whereas /3A280 gave the highest ac-
tivity level of aU vectors tested, which was 5 1 % higher than 
diat of Mg353. 
Regardless of the vector frames used, )3A promoter with M e 
consistentiy showed the highest expression activity in myotubes 
among the promoters tested. M e 4 could enhance the activity of 
R S V and CO650 m pdLhi vectors by 1.5- and 1.8-fold, re-
spectively, over those without Me. The enhanced expression 
levels of these vectors, however, were equivalent to the level 
only half of that of /3A constinct (pdLInMe4)3A280hDCml) 
(Fig. 7A). aAllS, another differentiated muscle cell specific 
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FIG. 6. hFDC expression activities of myogenin promoters 
Mgl03I and Mg353 in skeletal muscle cells. Assay conditions 
were similar to those in Fig. 2. The results from two constracts, 
pdLhdVIgl031hIXml (O) and pdLhiMg353hIXml (•) are 
shown. The arrow indicates medium switch for cell differenti-
ation. Results of a set of representative experiment with four 
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FIG. 7. Comparison of hFIX expression activities by vectors 
with different promoters with or without Me4. Experimental 
conditions were similar to those m Fig. 2. A. pdLIn vectors with 
or without Me4. pLIXSN is included as a reference vector. Thin 
lines with vertical bars indicate standard deviations of four du-
pUcated assays. Results shown are from the day 7 data of a rep-
resentative experiment. B. pdLi vectors with Me4. hFIX ex-
pressed on day 7 of two experiments is shown with the observed 
ranges. 
as shown for pdLihIXmlaA775Me4 and pdLihlXmlMg-
1031Me4 (Fig. 7B). 
The order of the promoter strength in pdL-type and pdLIn-
type vectors with M e 4 was determined with myotabes as, 
^A280 > Mg353 > Mgl031 « R S V = CO650 > CO1250 
(Fig. 7A, Table 2). Various promoters with M e 4 in the pdLi 
frame also gave a similar order in thek sttength, except that 
CO650 activity was only 5 2 % of Mgl031. hFIX expression lev-
els of pdLInMe4y3A280hDCml and pdLihIXmlj8A280Me4 in 
myotubes (160.7 ± 12.6 and 153.5 ± 16.8 ng/ml, respectively) 
were 15- to 16-fold and 30-fold higher than those of our pre-
vious vectors, pLIXSN and pdLMe2j3AliIX, respectively (Yao 
et al, 1994). In the present ttansient assay system, the latter 
two vectors expressed 10.2 ± 0.7 and 5.3 ± 2.3 ng/ml of hFDC, 
respectively (Table 2). 
Structure of highly refined expression vector 
O n the basis of the resuhs summarized above, the optimal 
basic sttuctare of the hFDC expression vector to be used for pro-
duction of hFDC by muscle-targeted gene transfer should con-
tain /3A promoter, M e 2 or Me4, and die hFDC minigene. Among 
the three vector frames used, only the pdLi-type frame should 
be able to prevent a loss of the expression-augmenting effects 
B 
1752 
WANG ET AL. 
of the mtton of hFDC mhiigene due to its splicmg m die pack-
aging ceUs. pdLi-type vectors with M e 4 expressed hFDC at the 
levels equivalent to the counterpart pdL and pdLIn vectors, ui-
dicating that the basic pdLi vector stracture fimctions weU. 
To constract a further refmed vector with the pdLi vector 
frame, J3A280 promoter was modified by tmncating its 5' 80-
bp sequence, where two potential polyadenylation signal se-
quences ( A A T A A A ) were present m the complementary sttand 
(Kost et al, 1993; MUler et al, 1988). In addition, several base 
substitations were also made to the remaining promoter se-
quence to eliminate aU other potential polyadenylation sites, 
thus generating a promoter )3A200. These modifications were 
done to eliminate possibilities of premature polyadenylation of 
the vkal genome R N A produced in the packagmg cells. A U of 
the removed or modified regions contain no known specific en-
hancer elements. /3A200 stiU retamed a promoter activity very 
shnUar to /3A280 as shown widi both hDCml and hDCm2 (Table 
2 and Fig. 7B). Because hIXm2 was also devoid of potential 
polyadenylation sites in the complementary sttands, which are 
present in the hDCml m its intton sequence region, we utUized 
hIXm2 in a highly optimized vector system with the pdLi vec-
tor frame. pdLihDCni2^A200Me4 expressed hFDC at a level of 
146.9 ng/ml mechum from myotabes, an equivalent level of that 
of pdLihIXmljS A280Me4, indicating no significant detrimen-
tal effects of these modifications of the /3A promoter and the 
hFDC minigene (Fig. 7B). 
Northern blot analysis of muscle cells transfected with 
hFIX expression vectors 
As shown hi Fig. 8, pdLMe4/3A280hIXml, pdLhiMe4;8A-
280hIXml, pdLihIXml/3A280Me4, and pdLihDCm2/3A-
200Me4 produced approximately equal amoimts of the major 
hFDC m R N A bands (~ 1.9 kb m lanes 7 and 8; ~ 1.6 kb m lanes 
5 and 6), which were produced by the intemal promoter, in my-
otalies on day 5 (thkd day after the iiutiation of differentiation). 
In myotabes, pdLihIXm2/3A200Me4 (lane 5) and pdLihDCml-
^A280Me4 (lane 6) produced approximately fotu- to five-fold 
more m R N A dian pdLihIXml/3A200 (lane 4). pdLihDCml/3-
A280Me4 produced a significantly less amount of m R N A in 
myoblasts (day 2) (lanes 2) in comparison to that in myotabes 
(day 5) (lanes 6). Tbese are consistent with the relative hFIX 
expression levels of these vectors observed in myotabes and 
myoblasts. Interestingly, pdLihIXml/3A200 also consistently 
gave a higher hFIX m R N A level in myotabes on day 5 than in 
myoblasts on day 2. 
DISCUSSION 
Skeletal muscle ceUs can be relatively easUy targeted for in 
vivo and ex vivo gene ttansfers and thek great potential to serve 
as an efficient and safe medium for producing various recom-
binant proteins has been demonsttated (Barr and Leiden, 1991; 
Dai et al, 1992; Yao and Kurachi, 1992; Bansal et al, 1994; 
Baque et al, 1994; Hamamori et al, 1995). To establish a 
durable muscle-targeted gene therapy, however, development 
of a highly refmed gene expression vector system has become 
one of the most critical issues. In tbe present stady, we con-
stracted a series of new hFDC expression vectors in three dif-
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FIG. 8. Northem blot analysis of muscle ceUs ttansfected with 
hFIX expression vectors. A. Lanes 1 and 2 contain 
poly(A)+RNA samples prepared from the myoblasts on day 2 
post ttansfection with pdLUiDCml/3A200 and pdLUiDCm-
lj8A280Me4, respectively. Lanes 4-8 contain poly(A)+RNA 
samples prepared from the myotabes derived from myoblasts 
on day 5 post ttansfection with pdLihIXml/3A200, pdLihDCm-
2)3A200Me4, pdLUiIXml;3A280Me4, pdLhiMe4/3A280hIX-
ml, and pdLMe4j8A280hIXmI, respectively. Lane 3 contains 
poly(A)+RNA prepared from the mock-ttansfected muscle 
cells. Numbers on the right side indicate R N A molecular weight 
marker. Arrows on the left side indicate the position of hFDC 
m R N A bands of —1.9 kb in lanes 7 and 8 and ~1.6 kb in lanes 
1, 2,4, 5, and 6, respectively. B. The presence of approximately 
equivalent R N A s m all lanes is shown by the presence of 18S 
ribosomal R N A . See the text for the experimental conditions. 
ferent rettovkal vector frames and systematically analyzed the 
relationship among vector stracture, expression components, 
and hFDC expression activity. 
Effects of different vector frames 
Three basic rettovkal vector frames, pdL, pdLIn, and pdLi 
(Fig. 1), provided us with an excellent model system to exam-
m e several critical issues in developing an optimal hFDC retto-
vkal vector stiTictiire. These issues mclude: (i) how high an ex-
pression level can be achieved by knprovmg pdL-type vectors; 
(u) how much effect does die MFG-type vkal mtton sequence 
contained m pdLhi-type vectors have on die intemal ttanscrip-
tional conttol unit; (iu) what is die relative sttengtii of die 5' 
LT R promoter in die different vector frames; (iv) what is die 
ttanscriptional activity level diat can be achieved by die mter-
nal hFDC expression unk widi pdLi m relation to pdL and pdLhi 
vectors; and (v) what is die basic vector frame to be included 
m an optunal hFDC rettovkal vector. 
pdL-type vectors, which are die simplest of die du«e vector 
frames tested in die present stady, were previously used m hu-
nrni gene dierapy of hypercholesterolemia (Grossman et al, 
1994). After a series of testings widi die hFDC minigene, dif-
terent promoters and additional muscle-specific enhancers 
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(Me), a specific combination of these components as repre-
sented in pdLMe4/8A280hIXml, gave the highest hFDC ex-
pression levels among the pdL vectors (Table 2). 
The pdLIn-type vectors, which have a MFG-derived vector 
intton sequence, were of particular interest because of their po-
tential for an elevated transgene expression. In recent years, the 
M F G rettoviral vector has been reported for its capability to ex-
press ttansgenes at substantial levels in various cell types such 
as hematopoietic cells (Ohashi et al, 1992; Dranoff et al, 
1993). More recendy, Dwarki etal (1995) reported a success-
ful expression of B-domain-deleted factor VHI in fibroblasts 
and endothelial cells, as well as myoblasts, by using a M F G 
rettoviral vector. In the present study, pdLIn vectors widiout 
any M e gave only slighdy better expression levels (20-30%) 
than thek counterpart pdL vectors (Table 2). The differences 
were statistically not significant. hFIX expression levels of 
pdLMe4;8A280hIXml and pdLhiMe4/3A280hIXml, which 
have sttong intemal hFIX expression activities, are very simi-
lar to each other (Table 2). 
These results indicate that: (i) the 5' LTR without or with 
the MFG-type viral intton sequence m the pdL and pdLIn vec-
tors does contribute to the overall hFIX expression, but not sig-
nificantly enough to affect the hFIX expression when the in-
temal hFDC expression unit is very sttong; and (u) neither a 
cryptic splicing acceptor site nor the splicing acceptor site of 
the hlXml intemal intton is likely to be used in combination 
with the splicing donor site in pdL-type vectors. The MFG-de-
rived intton is only partially spliced both in the packaging cells 
and ttansduced target cells (Dwarki etal, 1995). The vkal pack-
aging sequence is contained in the MFG-derived intron se-
quence and, therefore, the vkal RNAs of all recombinant M F G 
virases must contain the intton sequence. In the targeted ceUs, 
the intton is again partially spliced (Dwarki et al, 1995). In the 
ttansient assays, the MFG-derived intron of pdLIn vectors may 
be partially spUced, resulting in some mmor contribution to the 
hFDC production, particularly in the present of a sttong inter-
nal hFDC ttanscriptional unit, which has a much higher expres-
sion activity than the LTR in myotabes. 
When the M F G vector is used m a vkus form, ks transgene 
expression m die transduced target cells is lUcely elevated due 
to the positive effects of splicmg of the intton sequence, tiius 
resulting in an increased m R N A level for the ttansgene. As 
shown in Fig. 7 and Table 2, pdLihIXml;8A280Me4 has an ex-
pression activity equivalent to pdLMe4^A280hDCml and 
pdLInMe4/3A280hIXml, supporting diat, witii a strong inter-
nal promoter, neither die 5' LTR promoter nor the MFG-de-
rived intton significandy affects the overall hFIX expression 
activity of these vectors. This was consistent with the m R N A 
levels (Fig. 8). This sitaation is much different from the origi-
nal M F G vector, which uses ks LTR promoter to drive ex-
pression of the inserted gene (Dranoff et al, 1993; Dwarki et 
al, 1995). Presence of possible cryptic elements, which may 
function as A T G site(s) or prematare polyadenylation sites in 
the intemal enhancer and promoter regions of the pdLIn vec-
tors, may also minimize the effective use of m R N A s generated 
by die 5' LTR promoter m producmg hFIX. Such possibdities, 
however, may be minunal, because, in the absence of Me, pdLIn 
vectors appear to express marginally higher levels of hFDC than 
those of pdL vectors with various promoters (Table 2). 
Unless the intton sequence of hDCml is retamed in the ge-
nomic R N A of recombinant hFIX virases, no grossly elevated 
production of the hFDC m R N A due to the positive effects of 
such an intron can be expected in the target cells (Kurachi et 
al., 1995). The pdLi series of vectors was designed to test the 
basic vector stiiicture that can be used to prepare a rettovkal 
vector capable of preventing such a loss of the intemal intton 
due to splicing in the viral packagmg cells (Cone et al, 1987; 
Miller et al, 1988). pdLihIXmlMgl031, widi no Me, can only 
express hFIX at a level 2 1 % and 2 7 % of diose of 
pdLhiMgl031hIXml and pdLMgl031hIXml, respectively. 
These results indicate some contribution of the 5' LTR pro-
moter activity with or without the MFG-derived intton in pdLIn 
and pdL vectors. Altematively, transcripts generated by the 5' 
LTR may complex with the transcripts produced by the inter-
nal promoter in the reverse orientation, thus reducing the ef-
fective m R N A amount for producing factor DC. With a sttong 
intemal hFIX ttanscriptional unk as m pdLihIXmlMg353Me4 
or pdLihIXml/3A280Me4, the overaU expression activities as 
well as m R N A levels of the pdLi-type vectors becomes indif-
ferent from the counterpart constracts of pdLIn and pdL, indi-
cating that the modest contribution ofthe 5' LTR is easUy over-
come (Figs. 3, 7, and 8). 
These results indicate that the basic stracture of the pdLi-
type vectors should permit us to take a full advantage of the 
hFTX minigene. It is possible that LTR-driven transcription for 
producing the viras genomic R N A might be affected due to the 
sttong intemal promoter activity. Promoters with Me, a differ-
entiated muscle cell-specific enhancer, however, may function 
at the minimal efficiency in the fibroblast-derived packaging 
cells. Other possibilities, such as the presence of potential cryp-
tic splicing donor and acceptor sites in the pdLi-type vectors 
caimot be raled out (lonsson et al, 1995). These possibdities 
are currently being tested in our laboratory. 
Effects of additional muscle specific enhancer elements 
A region spanning nucleotides —1,351 to —1,050 of the 5'-
flanking sequence of the mouse M C K gene (designated M e in 
the present study) contains one CArG-box and two E boxes and 
shows a sttong differentiated muscle cell-specific enhancer ac-
tivity (Stemberg et al, 1988). This region not only enhances 
the M C K promoter (Stemberg et al, 1988) but also confers en-
hanced muscle-specific expression of heterologous gene pro-
moters such as simian viras 40, C M V , and c-fos (Stemberg et 
al, 1988; Dai et al, 1992; Martin et al, 1994). W e also re-
ported an augmentation of ;8A promoter activity by M e (Yao 
et al, 1994). In die present study, a systematic analysis of the 
enhancer effects of M e was carried out. With increasing copy 
numbers of Me, hFDC expression by pdL, pdLIn, and pdLi vec-
tors with not only muscle-specific promoters such as Mg, 
CO650, and aAllS, but also with non-muscle-specific pro-
moters such as RSV and )3A, was gready increased (Fig. 7). hi 
general. M e affects more sttongly die promoters with relatively 
weak basal activities, such as Mgl031, than those with sttong 
activities, such as RSV and C O (Figs. 6 and 7). This, however, 
appears to be very much dependent witii the promoter sequence, 
because /3A280, which has as sttong a basal activity as RSV 
and CO650, is also enhanced as much as Mg353. Expression 
of pdLi-type vectors is more affected by M e tiian diose of pdL-
or pdLhi-type vectors, suggesting that witiiin the rettovkal vec-
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tor frame M e primarily affects the closely linked intemal pro-
moter; die 5' L T R located at a distant position is less affected. 
Expression activities of different promoters 
Myogenin is one of the weU-defmed muscle-specific tran-
scriptional factors (Edmondson et al, 1992; Schwarz et al, 
1992). The M g promoter has a sttong specificity for differenti-
ated muscle ceUs and was used in the present stady as a model 
promoter for testing various conditions. As shown with 
pdLInMgl031hIXml, a long form of myogenin promoter, 
Mgl031, shows approximately 10-fold higher level of hFDC ex-
pression in myotabes than in myoblasts in good agreement with 
the previous observations (Edmondson et al, 1992). In the pres-
ent stady, the short form of the myogenin promoter Mg353 not 
only retained the differentiated muscle ceU specific activity, but 
its expression activity was also higher by about 1.6-fold than that 
of Mgl031 (Figs. 6 and 7). These observations suggest that the 
region spanning nucleotides —353 to —1,031, which is present 
only in Mgl031, and contains additional E boxes, contributes 
rather negatively to the transcriptional activity. This difference 
between Mgl03I andMg353 wasobservedregardlessof die vec-
tor t5fpe (pdL, pdLIn, or pdLi) and presence or absence of M e 
(see also Figs. 6 and 7). Interestingly, a short form of the calf 
C O promoter, CO650, also gave a substantially higher expres-
sion activity dian diat of die long form, CO1250 (Table 2). The 
proximal regions up to nucleotide —353 m the M g promoter and 
up to nucleotide —588 hi the C O promoter contain midtiple mus-
cle-specific enhancer elements (Edmondson et al, 1992; Lomax 
et al, 1995). It is not known at the present time why the longer 
forms, which contain additional enhancer elements, produce 
lower activities than the short form. The longer forms may also 
contain hitherto unidentified sUencer elements. Four M e copies 
increased the expression activity of CO650 by otdy 1.5-fold as 
observed for pdLhiCO650hIXml and pdLhiMe4CO650hDCml 
(Fig. 7A, Table 2). A sinular, rather poor enhancement of the 
R S V promoter (1.6-fold) with M e was also observed. ;3A280 has 
a basal activity equivalent to R S V and CO650 promoters, but its 
activity was enhanced three-fold with Me4, equivalent to that of 
Mg353 (3.2-fold) (Fig. 7A, Table 2). These results suggest diat 
the enhancer activity of M e is dependent on the promoter se-
quence in addition to the vector frame context as discussed above. 
ccA, another muscle-specific promoter, is as sttong as Mgl031 
m the presence of Me4. 
Among promoters tested, both ;8A280 and ;8A200 with M e 4 
consistentiy produce hFDC in muscle ceUs at the highest level 
in aU three vector frames. It is important to find that )3A200, 
which is modified from ;8A280, stiU has an expression activity 
comparable to /3A280. Presence of an increasing copy number 
of M e m the vector results m a higher hFDC expression. 
However, to minimize potential rearrangements of die vector 
D N A hi the process of gene ttansfer and chromosomal mte-
gration, as smaU as two M e copies, and not more than four 
copies, may be preferred. These multiple M e copies msure a 
substantial mcrease in hFDC production in skeletal muscle ceUs. 
Optimal basic structure of hFIX retroviral vector for 
skeletal muscle cells 
Through die systematic analyses carried out and as discussed 
above, we conclude that the basic stiuctare of a rettovkal vec-
tor for achieving an optimal hFIX expression ki differentiated 
muscle cells should have a pdLi vector frame witii an uitemal 
hFDC expression cassette composed of two (and no more than 
four) M e copies, |8A200 and hIXm2. pdLUiDCm2^A200Me2 
and pdLUiIXm2)3A200Me4 satisfy all of the conditions con-
sidered for maxunizing hFDC expression, hi ttansient assays, 
pdLihIXm2j8A200Me4 expressed hFDC at levels 15- or 30-fold 
higher than diose of the previous-generation rettovkal vectors, 
LIXSN or pdLMe2;8A280hDC, respectively (Table 2). These re-
finements made to the basic stiuctiue of die vector msure not 
only die enhanced muscle-specific, high-level expression of 
hFDC hi the target cells, but also possible preparation of re-
combmant vkus at a high yield m die packaging ceUs. The 3' 
LTR widi its enhancer deleted should assure a minimal kiter-
ference of hFDC expression dkected by die reversed intemal ex-
pression unk in the target cells. Preparation of recombinant 
vkuses of pdLUiIXm2;3A200Me2 and pdLUiDCm2/3A200Me4 
are in progress. 
The uitemal hFIX expression unk as well as each stiiictural 
component such as enhancer, promoter, and hFDC minigene of 
the vectors described in this stady have been constracted as ver-
satUe cassettes. They can be easUy ttansferred into various dif-
ferent types of vector systems such as adenoviras, A A V , or non-
vkal vector systems, and thek enhancer, promoter, or gene can 
also be easUy exchanged with others to target not oidy the FDC 
gene but also various other genes of interest into different ceU 
types and tissues. For example, proteins were produced at lev-
els as high as hFIX by replacing the hDCml sequence in 
pdLihIXml^A280Me4 with those of protem C or hiradin 
c D N A (unpublished data). 
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